The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Learnings from both Byetta and its own experience with Victoza helped Novo Nordisk develop and launch what it hopes will become a best in class therapy, with a strong life cycle management program and additional indications entering the clinic. The $12bn market for GLP-1 therapies has gotten crowded in recent years; Eli Lilly hopes its follow up to Trulicity (dulaglutide), the experimental combination product tirzepatide, a “dual glucose-dependent insulinotropic polypeptide (GIP) and GLP agonist," will help it maintain a leadership position. (Also see "Brand Spotlight: Novo Nordisk’s Semaglutide" - In Vivo, 15 April, 2021.) However, new indications in areas of massive unmet need, such as Alzheimer’s and obesity, could push Novo’s semaglutide over the top in the coming years. 

Dr. John Eng discovers a novel peptide hormone in the venom of a Gila monster

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.